;

Search Results:

Showing of 50

CLINICAL TRIAL17676

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL17929

A Phase I/II, Multicenter, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18390

A Phase 1 Dose Escalation, Multicenter, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 In Patients With Relapsed or Refractory Hematologic Malignancies

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18772

A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18950

A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19112

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Cancer Type: Multiple

View Trial Details

CLINICAL TRIAL19089

Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18083

Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m^2 IV daily for 3 days every month) versus Azacitidine (AZA; 75 mg/m^2 SC/IV daily for 3 days every month) versus Azcitidine (AZA; 75 mg/m^2 SC/IV daily for 5 days every month) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19203

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

Cancer Type: Malignant Hematology

View Trial Details